Protein Allostery in Rational Drug Design

被引:8
|
作者
Kinoshita, Takayoshi [1 ]
机构
[1] Osaka Prefecture Univ, Grad Sch Sci, Sakai, Osaka, Japan
来源
关键词
Protein kinase; Allosteric inhibitor; Structure-based drug discovery; High selectivity; CRYSTAL-STRUCTURES; KINASE INHIBITORS; BINDING; IDENTIFICATION; TARGET; POTENT; SITE; SELECTIVITY; MECHANISM; CK2-ALPHA;
D O I
10.1007/978-981-13-8719-7_3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This chapter focuses on protein kinases that transfer the phosphate group of ATP to the hydroxyl group of a substrate protein. Five hundred eighteen human protein kinases are classified into serine/threonine kinases and tyrosine kinases and individually or synergistically transduce physiologic stimuli into cell to promote cell proliferation or apoptosis, etc. Protein kinases are identified as drug targets because dysfunction of kinases leads to severe diseases such as cancers and autoimmune diseases. A large number of the crystal structures of the protein kinase inhibitor complex are available in Protein Data Bank and facilitated the drug discovery targeting protein kinases. The protein kinase inhibitors are classified into categories, Type-I, Type-II, Type-III, Type-IV, and Type-V, and as a separate class, covalent-type inhibitors. In any type, a protein kinase inhibitor bound to the allosteric region is advantageous in terms of selectivity compared to the traditional ATP-competitive one. In the following sections, the successful and promising examples of the partially or fully allosteric protein kinase inhibitors are illustrated in the following pages.
引用
收藏
页码:45 / 64
页数:20
相关论文
共 50 条
  • [31] From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
    Coelho, Edgar D.
    Arrais, Joel P.
    Oliveira, Jose Lus
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (05) : 602 - 618
  • [32] Structural dynamics and allostery of Rab proteins: strategies for drug discovery and design
    Kumar, Ammu Prasanna
    Verma, Chandra S.
    Lukman, Suryani
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (01) : 270 - 287
  • [33] THE CHEMISTRY OF RATIONAL PROTEIN DRUG STABILIZATION
    ROSER, BJ
    SEN, S
    COLACO, C
    CHILVERS, D
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 205 : 147 - BIOT
  • [34] RATIONAL DRUG DESIGN - A MULTIDISCIPLINARY APPROACH
    HUNTER, WN
    MOLECULAR MEDICINE TODAY, 1995, 1 (01): : 31 - 34
  • [35] Bioisosterism: A rational approach in drug design
    Patani, GA
    LaVoie, EJ
    CHEMICAL REVIEWS, 1996, 96 (08) : 3147 - 3176
  • [36] Structural bioinformatics for rational drug design
    Mozaffari, Soroush
    Moen, Agnethe
    Ng, Che Yee
    Nicolaes, Gerry A. F.
    Wichapong, Kanin
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)
  • [37] DRUG DESIGN - A RATIONAL ATTACK ON INFLUENZA
    TAYLOR, G
    NATURE, 1993, 363 (6428) : 401 - 402
  • [38] LIPIDS, LIPOSOMES, AND RATIONAL DRUG DESIGN
    JANOFF, AS
    LABORATORY INVESTIGATION, 1992, 66 (06) : 655 - 658
  • [39] PHARMACOKINETIC CONSIDERATIONS IN RATIONAL DRUG DESIGN
    GUMBLETON, M
    SNEADER, W
    CLINICAL PHARMACOKINETICS, 1994, 26 (03) : 161 - 168
  • [40] Rational drug design and PPAR agonists
    Perfetti R.
    D'Amico E.
    Current Diabetes Reports, 2005, 5 (5) : 340 - 345